

Emerging Therapy Solutions<sup>®</sup> (ETS) helps reinsurance and stop-loss payers, health plans, HMOs, and self-funded employers, along with third-party administrators and brokers, manage the risk associated with high-cost therapies for rare and complex conditions.

Programs listed here are manufacturer-approved treatment centers for which ETS has contracted rates in place or has access to rates through single case agreements for Omisirge (omidubicel-onlv) which is approved for patients 12 years and older with hematologic malignancies who are planned for umbilical cord blood transplantation following myeloablative conditioning to reduce the time to neutrophil recovery and the incidence of infection.

For assistance with your member referral or for more information, contact ETS at 877-445-4822 or by email at <u>medicalservices@emergingtherapies.com</u>.

State	City	Program Listing
Alabama	Birmingham	University of Alabama Health System
California	Stanford	Stanford Hospital and Clinics
	Los Angeles	U.C.L.A. Medical Center
Georgia	Atlanta	Northside Hospital
	Augusta	Wellstar MCG Health
Illinois	Chicago	Loyola University Medical Center
		Northwestern Memorial Hospital
Maryland	Baltimore	University of Maryland Medical Center
Massachusetts	Boston	Boston Children's Hospital
		Dana-Farber Cancer Institute
		Massachusetts General Hospital
Michigan	Ann Arbor	University of Michigan Medical Center
Nebraska	Omaha	Nebraska Medical Center
New York	New York	Mount Sinai Hospital
North Carolina	Durham	Duke University Hospital
Ohio	Columbus	James Cancer Center
Oregon	Portland	Oregon Health & Science University
Pennsylvania	Philadelphia	Thomas Jefferson University Hospital
Texas	Houston	Houston Methodist Hospital
		Texas Children's Hospital

© 2024 Emerging Therapy Solutions, Inc. All Rights Reserved. AP-11235. ETS is a trademark of Emerging Therapy Solutions, Inc. All other trademarks referenced herein are the property of their respective owners. The information provided here is believed to be accurate as of the listed document production date and is based on information currently available to us. Because facility and program changes may occur, please confirm details with our ETS clinical consultants at 877-445-4822 or medicalservices@emergingtherapies.com. Please note that coverage for any indicated services is subject to applicable plan documents. 10/31/2024